Drug-induced psychosis in Parkinson's disease: A review of management

CNS Drugs

Volumn 5, Issue 3, 1996, Pages 166-174

  Mendis, Tilak ^a,b   Lynn Barclay, C ^a   Mohr, Erich ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b SCO Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CLOZAPINE; ONDANSETRON; REMOXIPRIDE; RISPERIDONE;

DEMENTIA; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW;

EID: 9044224024     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605030-00003     Document Type: Review

References (63)

1. Hoehn M. Parkinson's disease: progression and mortality. Adv Neurol 1986; 45: 457-61
2. Yahr MD. Parkinson's disease: the L-DOPA era. Adv Neurol 1993; 60: 11-7
3. Goodwin FK. Psychiatric side-effects of levodopa in man. JAMA 1971; 218: 1915-20
4. Damasio AR, Lobo-Antunes J, Macedo C. Psychiatric aspects in parkinsonism treated with L-dopa. J Neurol Neurosurg Psychiatry 1971; 34: 502-7
5. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43: 2227-9
6. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995; 45: 669-71
7. Sharf B, Moskovitz C, Lupton MD, et al. Dream phenomena induced by chronic levodopa therapy. J Neural Transm 1978; 43: 143-51
8. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978; 135: 669-75
9. Rondot P, de Recondo J, Coignet A, et al. Mental disorders in Parkinson's disease after treatment with L-dopa. Adv Neurol 1984; 40: 259-69
10. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993; 43 Suppl. 6: S47-52
11. Celesia GG, Wanamaker WM. Psychiatric disturbances in Parkinson's disease. Dis Nerv Syst 1972; 33: 577-83
12. Stern Y, Marder K, Tang MX, et al. Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 1993; 43: 1690-2
13. Tanner CM, Vogel C, Goetz CG, et al. Hallucinations in Parkinson's disease: a population study [abstract]. Ann Neurol 1983; 14: 136
14. Loranger AW, Goodell H, Lee JE, et al. Levodopa treatment of Parkinson's syndrome: improved intellectual functioning. Arch Gen Psychiatry 1972; 26: 163-8
15. Meier MJ, Martin WE. Intellectual changes associated with L-dopa therapy. JAMA 1970; 213: 465-6
16. Botez MI, Barbeau A. Long-term mental changes in levodopa treated patients. Lancet 1973; 2: 1028-9
17. Mohr E, Fabbrini G, Ruggieri S, et al. Cognitive concomitants of dopamine system stimulation in Parkinsonian patients. J Neurol Neurosurg Psychiatry 1987; 50: 1192-6
18. Mohr E, Fabbrini G, Williams J, et al. Dopamine and memory function in Parkinson's disease. Mov Disord 1989; 4: 113-20
19. Sacks OW, Kohl MS, Messeloff CR, et al. Effects of levodopa in parkinsonian patients with dementia. Neurology 1972; 22: 516-9
20. Klawans HL. Psychiatric side effects during the treatment of Parkinson's disease. J Neurol Transm Suppl 1988; 27: 117-22
21. Weiner WJ, Koller WC, Perlik ST, et al. Drug holiday and management of Parkinson's disease. Neurology 1980; 30: 1257-61
22. Banerjee AK, Falkai PG, Savidge M. Visual hallucinations in the elderly associated with the use of levodopa. Postgrad Med J 1989; 65: 358-61
23. Lloyd KG, Hornykiewicz O. Occurrence and distribution of aromatic acid (L-dopa) decarboxylase in human brain. J Neurochem 1972; 19: 1549-59
24. Kalat JW. Biological psychology. 3rd ed. Belmont (CA): Wadsworth Publishing Co., 1988
25. Rinne UK. Brain neurotransmitter receptors in Parkinson's disease. In: Marsden CD, Fahn S, editors. Movement disorders. Boston: Butterworth Scientific, 1982: 59-74
26. Birkmayer W, Danielczyk W, Neumayer E, et al. Nucleus ruber and L-dopa psychosis: biochemical and post-mortem findings. J Neural Transm 1974; 35: 93-116
27. Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical post-mortem findings). J Neural Transm 1975; 37: 175-82
28. Melamed E, Zoldan J, Friedberg G, et al. Is hallucinosis in Parkinson's disease due to central serotonergic hyperactivity? Mov Disord 1993; 8: 406-7
29. Zoldan J, Friedberg G, Goldberg-Stern H, et al. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993; 341: 562-3
30. Fischer P, Danielczyk W, Simanyi M, et al. Dopaminergic psychosis in advanced Parkinson's disease. Adv Neurol 1990; 53: 391-7
31. Wilcox J. Psychoactive properties of amantadine. J Psychoactive Drugs 1985; 17: 51-3
32. Boyson SJ. Psychiatric effects of selegiline [letter]. Arch Neurol 1991; 48: 902
33. Vezina P, Mohr E, Grimes JD. Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects. Can J Neurol Sci 1992; 19: 142-6
34. Lieberman A, Kupersmith M, Estey E, et al. Treatment of Parkinson's disease with bromocriptine. N Engl J Med 1976; 295: 1400-4
35. Pearson KC. Mental disorders from low dose bromocriptine [letter]. N Engl J Med 1981; 305: 173
36. Jankovic J. Long term study of pergolide in Parkinson's disease. Neurology 1985; 35: 296-9
37. Koller WC, Silver DE, Lieberman A. An algorithm for the management of Parkinson's disease. Neurology 1994; 44 (12 Suppl. 10): S1-52
38. Friedman JH. Drug holidays in the management of Parkinson's disease: a brief review. Arch Intern Med 1985; 145: 913-5
39. Factor SA, Singer C. Neuroleptic malignant syndrome. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. Mount Kisco (NY): Futura, 1992: 199-230
40. Factor SA, Molho ES, Podskalny GD, et al. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995; 65: 115-38
41. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment resistant schizophrenic: a double blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96
42. Weintraub M, Evans P. Clozapine: a neuroleptic agent for selected schizophrenics and patients with tardive dyskinesia. Hosp Form 1989; 24: 16-27
43. Fitton A, Heel RC. Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990; 40: 722-47
44. Scholz E, Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 1985; 235: 60-4
45. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989; 39: 1219-21
46. Wolters EC, Hurwitz TA, Mak E, et al. Clozapine in the treatment of Parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40: 832-4
47. Kirkegaard A, Hensen A. An investigation of some side effects in 47 psychotic patients during treatment with clozapine and discontinuing of the treatment. Arzneimittelforschung 1979; 29: 851-8
48. Alvir JMJ, Lieberman JA, Safferman MD, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-7
49. Factor SA, Brown D. Clozapine prevents the recurrence of psychosis in Parkinson's disease. Mov Disord 1992; 7: 125-31
50. Pakkenherg H, Pakkenherg B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986; 73: 295-7
51. Kennen Jr JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993; 43: 1551-5
52. Megens AA, Awouters FH, Schotte A, et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 1994; 114: 9-23
53. Janssen PAJ, Niemegeers CJE, Awouters F, et al. Pharmacology of risperidone (R64 766), a new antipsychotic with serotonin S2 and dopamine D2 antagonistic properties. J Pharmacol Exp Ther 1988; 244: 685-93
54. Leysen JE, Gommeren W, Eens A, et al. The biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988; 247: 661-70
55. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease [letter]. Lancet 1994; 344: 681
56. Mendis T, Mohr E, Gray P, et al. Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride. Mov Disord 1994; 9: 197-200
57. Zoldan J, Friedberg G, Livneh M, et al. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45: 1305-8
58. Hurwitz TA, Calne DB, Waterman K. Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J Neurol Sci 1988; 15: 32-4
59. Douyen R, Serby M, Klutchko B, et al. ECT and Parkinson's disease revisited: a naturalistic study. Am J Psychiatry 1989; 146: 1451-5
60. Balldin J, Eden S, Granerus AK, et al. Electroconvulsive therapy in Parkinson's syndrome with 'on-off' phenomenon. J Neural Transm 1980; 47: 11-21
61. Andersen K, Balldin J, Gottfries CG, et al. A double-Wind evaluation of electroconvulsive therapy in Parkinson's disease with 'on-off' phenomena. Acta Neurol Scand 1987; 76: 191-9
62. Goetz CG, De Long MR, Penn RD, et al. Neurosurgical horizons in Parkinson's disease. Neurology 1993; 43: 1-7
63. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992; 76: 53-61